Are you Dr. Adelglass?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 36 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
6020 W Parker Rd
Ste 400
Plano, TX 75093Phone+1 972-492-6990Fax+1 972-394-4405
Summary
- Dr. Jeffrey Adelglass, MD is an otolaryngologist in Plano, Texas. He is currently licensed to practice medicine in Texas, Nevada, and Florida. He is affiliated with Texas Health Center for Diagnostic & Surgery and Texas Health Presbyterian Hospital Plano.
Education & Training
- New York Presbyterian Hospital (Columbia and Cornell Campus)Residency, Otolaryngology - Head and Neck Surgery, 1977 - 1980
- Universidad Autonoma de GuadalajaraClass of 1975
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- TX State Medical License 1981 - 2026
- NV State Medical License 2020 - 2025
- FL State Medical License 1988 - 2002
- NY State Medical License 1978 - 1992
- American Board of Otolaryngology - Head and Neck Surgery Otolaryngology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis Start of enrollment: 2007 Feb 01
- Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds Start of enrollment: 2010 Sep 27
- Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia Start of enrollment: 2014 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controll...Meagan E Deming, Elizabeth R Brown, Monica A McArthur, Stephanie J Schrag, Melissa Arvay
The Lancet. Microbe. 2025-01-27 - Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial.Chijioke Bennett, Gordon Chau, Erika Clayton, Laurence Chu, Jacqueline Alvarez
The Journal of Infection. 2025-01-26 - 1 citationsImmunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.Fritz Raiser, Matthew Davis, Jeffrey Adelglass, Miranda R Cai, Gordon Chau
Vaccine. 2023-09-22
Press Mentions
- Novavax COVID-19 Phase 3 Trial in North TexasDecember 29th, 2020
- Synexus Espande La Propria Capacità Globale E Debutta Nel Mercato Statunitense Con L'acquisizione Di Research Across AmericaMarch 1st, 2016
- Synexus Espande La Propria Capacità Globale E Debutta Nel Mercato Statunitense Con L'acquisizione Di Research Across AmericaMarch 1st, 2016
- Join now to see all
Professional Memberships
- Member